SC
ANTX icon

SummitTX Capital’s AN2 Therapeutics ANTX Stock Holding History

SummitTX Capital’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.89M Buy
+597,453
New +$2.57M 0.07% 278

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

SummitTX Capital's ANTX Position: Q2 2026 in Review

SummitTX Capital opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 597,453 shares worth $2.89M. The stake represents 0.07% of the portfolio and ranks #278 among its holdings.

57 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • SummitTX Capital held 597,453 shares of AN2 Therapeutics worth $2.89M as of Q2 2026.
  • AN2 Therapeutics was a new SummitTX Capital position in Q2 2026.
  • AN2 Therapeutics made up 0.07% of SummitTX Capital's portfolio in Q2 2026, its #278 holding.
  • 57 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.